Author | Curcumin | Placebo | ||||
---|---|---|---|---|---|---|
N | Mean | SD | N | Mean | SD | |
(a) ROM preexercise | ||||||
Tanabe Y | 14 | 134 | 4 | 14 | 133 | 5 |
Tanabe Y | 8 | 136.47 | 4.71 | 8 | 135.69 | 7.84 |
Tanabe Y (pre) | 10 | 133.85 | 9.24 | 10 | 133.85 | 6.16 |
Tanabe Y (post) | 10 | 136.92 | 6.93 | 10 | 133.85 | 6.93 |
UMD (95% CI) | 1.18 (− 1.30, 3.67) | |||||
(b) ROM post-exercise | ||||||
Tanabe Y | 14 | 115.03 | 12.64 | 14 | 112.31 | 12.64 |
Tanabe Y | 8 | 116.86 | 6.27 | 8 | 110.59 | 16.47 |
Tanabe Y (pre) | 10 | 116.2 | 5.39 | 10 | 117.69 | 3.08 |
Tanabe Y (post) | 10 | 119.28 | 110.77 | 10 | 110.04 | 12.32 |
UMD (95% CI) | − 0.30 (− 3.71, 3.11) | |||||
(c) ROM at 24 h | ||||||
Tanabe Y | 14 | 116.76 | 12.07 | 14 | 113.46 | 9.196 |
Tanabe Y | 8 | 112.98 | 10.98 | 8 | 113.73 | 11.76 |
Tanabe Y (pre) | 10 | 109.23 | 5.39 | 10 | 112.31 | 9.23 |
Tanabe Y (post) | 10 | 119.28 | 9.23 | 10 | 108.5 | 11.55 |
UMD (95%CI) | 2.30 (− 3.78, 8.37) | |||||
(d) ROM at 48 h | ||||||
Tanabe Y | 14 | 118.48 | 12.64 | 14 | 114.03 | 8.62 |
Tanabe Y | 8 | 106.67 | 12.55 | 8 | 105.88 | 14.11 |
Tanabe Y (pre) | 10 | 103.11 | 6.16 | 10 | 107.69 | 12.31 |
Tanabe Y (post) | 10 | 118.51 | 9.23 | 10 | 100.8 | 13.08 |
UMD (95%CI) | 4.57 (− 4.85, 14.00) 4.57 (− 4.85, 14.00) | |||||
(e) ROM at 72 h | ||||||
Tanabe Y | 14 | 119.06 | 12.64 | 14 | 114.61 | 14.94 |
Tanabe Y | 8 | 106.67 | 17.25 | 8 | 98.04 | 15.69 |
Tanabe Y (pre) | 10 | 106.19 | 16.94 | 10 | 103.85 | 14.62 |
Tanabe Y (post) | 10 | 120.05 | 10.77 | 10 | 96.95 | 15.38 |
UMD (95%CI) | 9.84 (− 0.02, 19.70) | |||||
(f) ROM at 96 h | ||||||
Tanabe Y | 14 | 122.51 | 11.49 | 14 | 116.33 | 11.49 |
Tanabe Y | 8 | 109.8 | 18.82 | 8 | 103.53 | 10.98 |
Tanabe Y (pre) | 10 | 110.04 | 9.24 | 10 | 110.77 | 16.16 |
Tanabe Y (post) | 10 | 123.85 | 9.23 | 10 | 103.88 | 10.77 |
UMD (95%CI) | 8.45 (− 0.84, 17.74) |